n the elderly population unrecognized heart failure is very common in patients with stable chronic obstructive pulmonary disease (COPD), 1 and the high prevalence of COPD, chronic heart failure (CHF) and their combination in this group [2] [3] [4] suggests that customized treatment may be required for such complicated disease status. We report using tiotropium, a non--adrenergic bronchodilator and novel M3 muscarinic receptor antagonist, for COPD complicated with CHF.
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Case Report
A 77-year-old man was referred to hospital because of dyspnea on exertion. He was a heavy smoker of 60 cigarettes/day for 34 years and had CHF with history of hypertension and mild aortic regurgitation (AR) for 7 years, for which he was being treated with an angiotensin-converting enzyme inhibitor (temocapril, 2 mg) and loop diuretics (furosemide, 20 mg). His weight, blood pressure and heart rate were 56.8 kg, 124/64 mmHg and 80 beats/min, respectively. The breath sounds were decreased with fine rales in both of the posterior lung bases. Physical examination revealed no overt signs of right-sided heart failure, such as dilated jugular vein, hepatomegaly or peripheral edema.
Chest X-ray showed increased fibro-linear infiltration in both lung bases ( Fig 1A) and ECG revealed sinus rhythm with complete right bundle branch block and high voltage in the chest leads (Fig 1B) . Laboratory investigations were normal except for a high concentration of brain natriuretic peptide (BNP: 222 pg/ml), which had been chronically elevated at approximately 200-300 pg/ml at least for 2 years.
Echocardiography revealed left ventricular (LV) hypertrophy with an enlarged LV cavity and diffuse hypokinesis of the LV wall, with an ejection fraction (EF) of 27%. Right ventricular (RV) dimensions and wall motion were normal. The inferior vena cava showed respiratory movement and was not enlarged. Doppler echocardiography showed early diastolic transmitral flow velocity (E) of 1.2 m/s and the peak diastolic velocity during early filling of the longitudinal mitral annular motion (Ea) was 9.9 cm/s (Fig 2) . The E/Ea ratio was 12.2, indicating high LV end-diastolic pressure (LVEDP). 5 The E/A ratio was 0.67, which indicated an abnormal relaxation pattern. Doppler echocardiographic estimated pressure gradient between right atrial (RA) and RV was 22 mmHg (Table 2 ) and systolic pulmonary artery (PA) pressure was 32 mmHg, indicating hemodynamic load on the right side of the heart. Right-heart catheterization, coronary angiography (CAG) and left ventriculography (LVG) were performed. Pulmonary capillary wedge pressure was 16 mmHg, PA pressure was 30/12 mmHg (mean PA pressure =22 mmHg), RA pressure was 4 mmHg and cardiac output was 5.6 L/min. Pulmonary vascular resistance was 86 dyne· s -1 ·cm -5 . CAG showed normal coronary arteries. LVG revealed diffuse hypokinesis with EF of 30% and mild AR. LVEDP was 14 mmHg. Therefore, we diagnosed left-sided heart failure and hemodynamic load on the right heart with neither pulmonary hypertension nor right-sided heart failure.
Pulmonary functional examination revealed a forced expiratory volume in 1 s (FEV1) of 0.86 L (42.1% of predicted normal value), which was 40.7% of forced vital capacity (FVC), indicating COPD. 6 Taking all the findings together, we diagnosed CHF caused by hypertensive heart disease with severe COPD. His cardiac performance had not significantly changed for several years. A 77-year-old man was referred to hospital because of dyspnea on exertion. Although the patient had been fully medicated for chronic heart failure (CHF) caused by hypertensive heart disease, the echo-estimated left ventricular end-diastolic pressure (LVEDP) and brain natriuretic peptide (BNP) level had continued to be high for at least 2 years. Pulmonary functional examination revealed concomitant chronic obstructive pulmonary disease (COPD). Because -agonists were expected to exacerbate the CHF, inhalation of tiotropium, a non--adrenergic bronchodilator and novel M3 muscarinic receptor antagonist, was used to treat the COPD. Not only did the pulmonary function improved but the treatment also safely ameliorated CHF signs including LVEDP and plasma BNP. (Circ J 2006; 70: 1658 -1660)
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One month later, he started inhalation of tiotropium, 18 g/day and the other medications were unchanged. Twenty-eight days after the onset of the inhalation treatment, the patient had substantially improved health-related quality of life (HRQOL) as determined by the St George's Respiratory Questionnaire (SGRQ), 7 exercise capacity, the E/Ea ratio, and also plasma norepinephrine and BNP levels (Table 1) , without significant changes in RV function as evaluated by conventional echocardiography (Table 2) .
Six months later, the patient is stable in New York Heart Association (NYHA) class I, without adverse effects of tiotropium, such as thirst, skin eruptions, premature ventricular contractions, or allergic reactions. 
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Discussion COPD is a disease state characterized by airflow limitation that is not fully reversible and is usually progressive, together with abnormal inflammatory responses in the lung to noxious particles or gases. The diagnosis is confirmed by spirometry as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Scientific Committee. 6 In the present case, a postbronchodilator FEV1 of 42.1% of the predicted value in combination with an FEV1/FVC of 40.7% convinced us that the severe COPD needed specific medical treatment for its symptoms.
Enhanced sympathetic nerve activity, as evidenced by increased plasma norepinephrine level, has been detected in patients with COPD, 8 and has an impact on CHF symptoms because sympathetic activation is deleterious for the pathophysiology of CHF. Therefore, using a -agonist bronchodilator may be deleterious for CHF, even if the COPD improved. 9 Such patients appear to be more effectively treated with anticholinergic drugs than with -agonists, 10 because -adrenergic receptor stimulation of sympathetic nerve activation exacerbates CHF. 11 Therefore, we decided to use tiotropium, which is a novel anticholinergic bronchodilator that is inhaled once daily by patients with COPD and its effect is mediated through a prolonged M3 muscarinic receptor antagonism. 12 The effects of tiotropium inhalation on pulmonary function, NYHA functional class, exercise capacity, HRQOL were beneficial in the present case (Table 1 ). Although we considered that the therapy may exacerbate CHF because of its cholinergic effects (eg, tachycardia, activation of sympathetic nerve system), the plasma levels of norepinephrine and BNP were significantly decreased. Echocardiography after the inhalation treatment revealed that the left atrial dimension had decreased from 41 to 36 mm, the Ea increased from to 9.6 to 12.8 cm/s (Fig 2) and the E/Ea ratio was decreased from 12.6 to 10.2 (Table 2) , which reflected the decrease in the LVEDP. 5 BNP is a biomarker of CHF because it is continuously released from the heart in response to ventricular volume expansion and pressure overload. 13 Therefore, in the present case a decrease in the LVEDP might be related to a decrease in the BNP level. Thus, the decrease in the BNP level after tiotropium inhalation might reflect improvement in not only the hemodynamic load on the right-side of the heart but also the left-sided heart failure.
COPD causes blood gas abnormalities, followed by sympathetic nerve activation via stimulation of chemosensitive carotid bodies. Treatment with a bronchodilator for mild to moderate COPD improves respiratory function and exercise tolerance, but does not improve gas exchange abnormalities in the absence of oxygen therapy. 14 Nonetheless, in the present case tiotropium inhalation improved the airway obstruction and also suppressed activation of the sympathetic nerve system via an improvement in both the negative intrathoracic pressure 15, 16 and the continuous fatigue of the respiratory muscles. Indeed, the plasma norepinephrine level was decreased significantly.
The treatment of COPD with inhaled tiotropium, a non--agonist bronchodilator, resulted in improvement of COPD without exacerbation of the coexistent CHF, reflected in the decrease in both the BNP and serum norepinephrine levels. In the not-too-distant future, the number of elderly patients with both COPD and CHF will increase acutely in Japan. Because high BNP levels are associated with poor survival in patients with CHF, 17 tiotropium has the potential to modify the morbidity and mortality of the patients with both conditions. Thus, further investigation of the effects of tiotropium on the symptoms of left-sided heart failure in a large population is required.
